BLA Submitted to FDA for PET Imaging Agent TLX250-CDx in RCC

A biologics license application seeking the approval of the investigational positron emission tomography imaging agent 89Zr-DFO-girentuximab in clear cell renal cell carcinoma has been submitted to the FDA.

Related Keywords

Cdx Zircaix ,Brian Shuch ,James Stonecypher ,Alvin Carrie Meinhardt ,Christian Behrenbruch ,Institute Of Urologic Oncology ,Telix Group ,Kidney Cancer Program ,Kidney Cancer Research ,Cancers Symposium ,Carrie Meinhardt Endowed Chair ,Urologic Oncology ,Bernhardj C ,News ,Genitourinary Cancers ,Gu Cancer ,Nrcc ,Renal Cell Carcinoma ,Kidney Cancer ,Clear Cell Renal Carcinoma ,Fda ,